These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33027549)

  • 1. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
    Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
    Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
    Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
    Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
    Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
    Rrapaj E; Giacometti L; Spina P; Salvo M; Baselli GA; Veggiani C; Rena O; Trisolini E; Boldorini RL
    Pathology; 2021 Jun; 53(4):462-469. PubMed ID: 33272690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
    Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
    Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
    Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
    Wang Y; Deng J; Wang L; Zhou T; Yang J; Tian Z; Yang J; Chen H; Tang X; Zhao S; Zhou L; Tong A; Xu J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of B7 family checkpoint proteins in cervical cancer.
    Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
    Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.